Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2023-03-07 Regulatory Filings
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Kliniske fase IIb studie, (HeROPA-studien), godkjent for start i Norge, Finland, Tyskland og Polen
Regulatory Filings Classification · 95% confidence The document is a short announcement (2365 characters) written in Norwegian, detailing the approval for a Phase IIb clinical study (HeROPA-studien) for their drug candidate HRO350 to start in several new countries (Norway, Finland, Germany, Poland), in addition to the UK approval previously announced. It references prior stock exchange announcements ('børsmelding') and states that the information is subject to disclosure requirements ('informasjonspliktig etter verdipapirhandelloven § 5-12'). This type of material update regarding clinical trials, regulatory milestones, or operational progress, when presented as a brief announcement rather than a full report, typically falls under general regulatory announcements or specific operational updates. Since there is no specific category for 'Clinical Trial Update' and it is not a financial report (10-K, IR, ER), nor a management change (MANG) or financing event (CAP), it fits best as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update (LTR) if the focus was on the approval process itself. Given the context of a brief, material operational update that must be disclosed, RNS (Regulatory Filings - general fallback for miscellaneous regulatory announcements) is the most appropriate classification, adhering to the 'MENU VS MEAL' rule as it is an announcement, not the full study protocol or results.
2023-03-07 Norwegian
Arctic Bioscience - Styrets godkjennelse av kapitaløkning relatert til utøvelse av aksjeopsjoner
AGM Information Classification · 93% confidence The document is explicitly titled "PROTOKOLL FRA STYREMØTE" (Minutes from Board Meeting) and details resolutions passed by the board, specifically concerning a "Forhøyelse av selskapets aksjekapital" (Share capital increase) and subsequent amendments to the articles of association. This content relates directly to corporate governance, capital structure changes, and formal board decisions. While it involves capital changes (CAP) and governance (CGR), the primary nature of the document is the formal record of a board meeting, which is a type of internal governance document. However, none of the provided codes perfectly match 'Board Meeting Minutes'. Given the content focuses heavily on a capital increase (SHA/CAP) and board resolutions, I must select the closest fit. Since the document details the formal resolution to increase capital and amend bylaws based on prior authorization, it strongly relates to capital structure changes. The closest specific category related to capital changes is 'Capital/Financing Update' (CAP). However, the document is a formal protocol/minutes, which often falls under general governance or regulatory filings if not explicitly covered. Since the core action is a capital increase, 'CAP' is a strong candidate, but 'SHA' (Share Issue/Capital Change) is also highly relevant. Since the document is the formal record of the decision to execute the capital change, and not just the announcement of the change itself, it is a formal internal document. Given the options, 'CAP' (Capital/Financing Update) or 'SHA' (Share Issue/Capital Change) are the most relevant actions described. Since the document details the mechanics of the capital increase, 'SHA' is slightly more precise than the general 'CAP'. Alternatively, if this is considered a formal internal governance record not covered elsewhere, it might default to RNS, but the content is too specific. I will classify it as 'SHA' as the primary subject is the resolution for a share capital increase.
2023-03-07 Norwegian
Arctic Bioscience - Board approval of share capital increase related to share option exercise
AGM Information Classification · 93% confidence The document is explicitly titled "PROTOKOLL FRA STYREMØTE" (Minutes from Board Meeting) and details resolutions passed by the board, specifically concerning a "Forhøyelse av selskapets aksjekapital" (Share capital increase) and subsequent amendments to the articles of association. This content relates directly to corporate governance, capital structure changes, and formal board decisions. While it involves capital changes (CAP) and governance (CGR), the primary nature of the document is the formal record of a board meeting, which is a type of internal governance document. However, none of the provided codes perfectly match 'Board Meeting Minutes'. Given the content focuses heavily on a capital increase (SHA/CAP) and board resolutions, I must select the closest fit. Since the document details the formal resolution to increase capital and amend bylaws based on prior authorization, it strongly relates to capital structure changes. The closest specific category related to capital changes is 'Capital/Financing Update' (CAP). However, the document is a formal protocol/minutes, which often falls under general governance or regulatory filings if not explicitly covered. Since the core action is a capital increase, 'CAP' is a strong candidate, but 'SHA' (Share Issue/Capital Change) is also highly relevant. Since the document is the formal record of the decision to execute the capital change, and not just the announcement of the change itself, it is a formal internal document. Given the options, 'CAP' (Capital/Financing Update) or 'SHA' (Share Issue/Capital Change) are the most relevant actions described. Since the document details the mechanics of the capital increase, 'SHA' is slightly more precise than the general 'CAP'. Alternatively, if this is considered a formal internal governance record not covered elsewhere, it might default to RNS, but the content is too specific. I will classify it as 'SHA' as the primary subject is the resolution for a share capital increase.
2023-03-07 English
Arctic Bioscience - Styrets godkjennelse av kapitaløkning relatert til utøvelse av aksjeopsjoner
Share Issue/Capital Change Classification · 98% confidence The document text is a short announcement (2095 characters) detailing the board's approval of a capital increase resulting from the exercise of stock options. It specifies the exact number of new shares issued (50,000), the nominal value, the subscription price, and the resulting total share capital. This action directly relates to changes in the company's capital structure due to employee/insider option exercise. This fits the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core event is the formal increase of share capital following an option exercise, SHA is the most precise fit, as it covers capital structure changes and new share issues. It is not a general earnings release (ER) or a full annual report (10-K). Given the explicit mention of increasing the share capital ('øke aksjekapitalen') and issuing new shares ('utstedelse av nye aksjer'), SHA is the correct classification.
2023-03-07 Norwegian
Arctic Bioscience - Board approval of share capital increase related to share option exercise
Share Issue/Capital Change Classification · 98% confidence The document explicitly details a resolution by the Board of Directors to increase the share capital due to the exercise of share options. It specifies the old and new capital amounts, the number of new shares issued, the subscription price, and the resulting total number of shares. This action directly relates to changes in the company's capital structure through the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it mentions an attached 'Minutes from Board Meeting', the core content is the capital change announcement itself, not just the announcement of a report (which would suggest RPA or RNS).
2023-03-07 English
Arctic Bioscience - Exercise of share options and issuance of shares
Director's Dealing Classification · 100% confidence The document is structured as a formal notification template detailing a transaction involving a person discharging managerial responsibilities (Daniele Mancinelli, CTO) and the issuer (Arctic Bioscience AS). Specifically, it reports a 'Share Purchase' of 'Share option linked to a share option programme' on a specific date. This perfectly matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2023-02-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.